This CME/CE accredited webinar entitled “Feeling Better After Feeling Worse: Navigating Patients through the Cortisol Withdrawal Syndrome after Treatment of Cushing Syndrome” features expert discussion on how to best navigate patients through the cortisol withdrawal syndrome after treatment of Cushing Syndrome.

The target audience for this webinar is physicians, nurses and other allied healthcare providers treating patients with Cushing Syndrome.

As a result of viewing this webinar, learners should be able to:

• Identify glucocorticoid withdrawal symptoms and describe the complexities of managing and differentiating from adrenal insufficiency

• Discuss and share strategies for glucocorticoid dosing and tapering, hypothalamic-pituitary-adrenal (HPA) axis testing, as well as pharmacotherapy and ancillary treatments for glucocorticoid withdrawal symptoms management

• Educate patients in navigation from glucocorticoid withdrawal symptom and adrenal insufficiency to full HPA axis recovery

Maria Fleseriu, MD
Professor Medicine and Neurological Surgery
Director Pituitary Center
Oregon Health & Science University
Portland, Oregon

Richard J. Auchus, MD, PhD
The James A. Shayman and Andrea S. Kevrick
Professor of Translational Medicine
Division of Metabolism, Endocrinology, & Diabetes
Departments of Internal Medicine and Pharmacology
University of Michigan
Ann Arbor, Michigan

Irina Bancos, MD
Associate Professor of Medicine
Division of Endocrinology
Joint Appointment Department of Laboratory
Medicine and Pathology
Mayo Clinic
Rochester, Minnesota

Eliza B. Geer, MD
Medical Director, Multidisciplinary Pituitary
and Skull Base Tumor Center
Associate Attending, Medicine and Neurosurgery
Memorial Sloan Kettering Cancer Center
New York, New York

Physician Accreditation Statement

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Your CE Source and CMM Global. Your CE Source is accredited by the ACCME to provide continuing medical education for physicians.

Your CE Source designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nursing Accreditation Statement

Your CE Source is an approved provider of continuing nursing education by the California Board of Registered Nursing. Provider approved by California Board of Registered Nursing, Provider #16031 for 1.0 contact hours.

Maria Fleseriu, MD has disclosed that she has received research support to OHSU from Recordati Rare Diseases and Strongbridge/Xeris as well as occasional consulting fees from HRA Pharma, Recordati Rare Diseases, Sparrow, and Strongbridge/Xeris.

Richard J. Auchus, MD, PhD has disclosed that he has received research support from Corcept Therapeutics, Diurnal, Ltd., Neurocrine Biosciences, Norvartis Pharmaceuticals, and Spruce Biosciences as well as occasional consulting fees from Adrenas Therapeutics, Corcept Therapeutics, Crinetics Pharmaceuticals, H. Lundbeck A/S, Janssen Pharmaceuticals, Novartis Pharmaceuticals, PhaseBio Pharmaceuticals, Quest Diagnostics, Recordati Rare Diseases, and Strongbridge Biopharma/Xeris Pharmaceuticals.

Irina Bancos, MD has disclosed that she has received occasional consulting fees from Adrenas Therapeutics, Corcept Therapeutics, HRA Pharma, Lantheus Holdings, Recordati Rare Diseases, Sparrow, Spruce Biosciences and Strongbridge Biopharma/Xeris Pharmaceuticals.

Eliza B. Geer, MD has disclosed that she has received research support from Chiasma/Amryt Pharma, Corcept Therapeutics, Ionis Pharmaceuticals, Novartis Pharmaceuticals, Recordati Rare Diseases, and Strongbridge Biopharma/Xeris Pharmaceuticals as well as occasional consulting fees from Chiasma/Amryt Pharma, HRA Pharma, and Strongbridge Biopharma/Xeris Pharmaceuticals.

All other faculty, planner and/or content managers of Your CE Source and CMM Global have nothing to disclose nor do they have any vested interests or affiliations. All conflicts of interest have been mitigated by attestation statements and peer review.